Condition
Adamantinomatous Craniopharyngioma
Total Trials
3
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (1)
P 2 (1)
Trial Status
Recruiting2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05919264Phase 1Recruiting
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05233397Phase 2RecruitingPrimary
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
NCT03970226Early Phase 1Active Not RecruitingPrimary
Tocilizumab in Children With ACP
Showing all 3 trials